Aspen's Parkinson's cell therapy takes an RMAT designation

The FDA granted regenerative medicine advanced therapy designation to sasineprocel, the San Diego company Aspen Neuroscience said on 30 July 2026. The therapy, coded ANPD001, takes a patient’s own cells, reprograms them into dopaminergic neuron precursor cells, and delivers them surgically into the putamen — the part of the brain that loses dopamine signalling in Parkinson’s disease. Because the cells are the patient’s own, the approach is meant to avoid the immunosuppression that donor-derived grafts require.

The designation rests on early safety and activity data from ASPIRO, an open-label, multicohort, multicentre Phase 1/2a study that is still running. Aspen already held a Fast Track designation for the programme. RMAT is a procedural status, not a finding of efficacy: it buys earlier and more frequent contact with the agency and access to the same expedited machinery as breakthrough therapy. Chief executive Damien McDevitt called it a milestone for a potentially disease-modifying treatment.

Parkinson’s is treated today by replacing the chemical the dead neurons no longer make. A cell therapy proposes replacing the neurons. Whether the graft survives, wires in, and holds up over years is what the trial has yet to answer — the designation only says the regulator has agreed to watch more closely while it does.